Cited 4 times in

State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis

Authors
 Yongin Cho  ;  Yong-Ho Lee 
Citation
 Endocrinology and Metabolism (대한내분비학회지), Vol.37(1) : 38-52, 2022-02 
Journal Title
Endocrinology and Metabolism(대한내분비학회지)
ISSN
 2093-596X 
Issue Date
2022-02
MeSH
Humans ; Hypoglycemic Agents / therapeutic use ; Liver Cirrhosis ; Non-alcoholic Fatty Liver Disease* / drug therapy ; Non-alcoholic Fatty Liver Disease* / pathology
Keywords
Clinical trial ; Non-alcoholic fatty liver disease ; Review ; Therapeutics
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, and non-alcoholic steatohepatitis (NASH), a subtype of NAFLD, can progress to cirrhosis, hepatocellular carcinoma, and death. Nevertheless, the current treatment for NAFLD/NASH is limited to lifestyle modifications, and no drugs are currently officially approved as treatments for NASH. Many global pharmaceutical companies are pursuing the development of medications for the treatment of NASH, and results from phase 2 and 3 clinical trials have been published in recent years. Here, we review data from these recent clinical trials and reports on the efficacy of newly developed antidiabetic drugs in NASH treatment.
Files in This Item:
T202201712.pdf Download
DOI
10.3803/EnM.2022.102
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Yong Ho(이용호) ORCID logo https://orcid.org/0000-0002-6219-4942
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188773
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links